RESUMEN
Azole therapy is widely utilized in hematopoietic stem cell transplant (HCT) recipients for the treatment of aspergillus. Complications of voriconazole treatment related to its elevated fluoride content have been described in adults, including reports of symptomatic skeletal fluorosis. We review fluoride levels, clinical, and laboratory data in five pediatric HCT recipients on long-term voriconazole therapy, all found to have elevated serum fluoride levels. Two patients had toxic fluoride levels, one infant had symptoms of significant pain with movement and radiographs confirmed skeletal fluorosis. Monitoring fluoride levels in children, especially with skeletal symptoms, should be considered in patients on long-term voriconazole.
Asunto(s)
Enfermedades Óseas/inducido químicamente , Fluoruros/sangre , Neoplasias Hematológicas/complicaciones , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Periostitis/inducido químicamente , Voriconazol/efectos adversos , Adulto , Antifúngicos/efectos adversos , Enfermedades Óseas/sangre , Niño , Preescolar , Terapia Combinada , Femenino , Estudios de Seguimiento , Neoplasias Hematológicas/microbiología , Neoplasias Hematológicas/terapia , Humanos , Lactante , Masculino , Pronóstico , Receptores de Trasplantes , Adulto JovenRESUMEN
Multidrug-resistant (MDR) Enterobacteriaceae infections are associated with increased morbidity. We describe a 20-year-old hematopoietic cell transplantation recipient with recurrent MDR Klebsiella pneumoniae infection, prolonged intestinal colonization, and subsequent intestinal decontamination. Further study should evaluate stool surveillance, molecular typing, and fecal microbiota transplantation for patients with intestinal MDR Enterobacteriaceae carriage.